By

Lundbeckfonden
Lund, Sweden, 18:00 CET, 16 August 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that its antibiotic-eluting product CERAMENT G has been approved by Health Canada. CERAMENT G is the first and only CE-marked gentamicin-eluting injectable ceramic bone graft substitute on the market. CERAMENT G sales have been...
Et forskerhold har haft succes med at oprette det første ’bibliotek’ over særlige sukkerstrukturer, der er livsvigtige for mennesker. Arbejdet har været ledet af forskere fra Københavns Universitet, og biblioteket giver blandt andet nye muligheder for at studere sygdomme. Vores celler reguleres af en lang række faktorer og processer – både når vi er raske,...
August 14, 2018 Spero adds broad leadership and scientific expertise to its Board of Directors with appointment of John Pottage CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the appointment of John...
Palma, Spain and San Diego, USA, August 6th, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the completion of enrollment of its Phase 2b CaLIPSO clinical trial investigating Sanifit’s lead candidate SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD). Most...
I disse dage forbereder fem dygtige medicinstuderende sig på at deltage i Lundbeckfondens forskningsprogram DARE – Danish American Research Exchange. De fem studerende er rejst til San Francisco, hvor de skal forske på Stanford University og University of California, San Francisco. Mette, Cecilie, Mark, Søren og Emma er rejst over Atlanten for at forske i...
Lund, Sweden, 08:00 CET, 2 August 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, has signed an agreement with MTF Biologics, the world’s largest tissue bank, to extend and strengthen its US product offering. The agreement will give BONESUPPORT US rights to two forms of bone graft materials comprised...
SAN DIEGO and COPENHAGEN, Denmark, July 23, 2018 /PRNewswire/ — Dermtreat, a clinical-stage biopharmaceutical company focused on mucosal diseases, today announced treatment of the first patient in a Phase 2b clinical trial of Rivelin® Clobetasol patch (Rivelin®-CLO) for oral lichen planus (OLP). Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol...
New Haven, CT, July 19, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic conditions, announced today that it has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations....
Lund, Sweden, 18:30 CET, 18 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that Michael Diefenbeck MD PhD, BONESUPPORT’s Chief Medical Officer, has been appointed to assume a broader role as Head of R&D, Medical and Clinical Affairs. Emil Billbäck, CEO of BONESUPPORT, commented: “We are pleased...
Dysis Medical, som har udviklet et digitalt kolposkop, der bruges i diagnosticering af livmoderhalskræft, skal sætte yderligere fart på væksten med en investering på 150 mio. kr. fra Lundbeckfonden Ventures. Livmoderhalskræft koster på verdensplan 250.000 kvinder livet hvert år, men med et særligt digitalt kolposkop udviklet af britiske Dysis Medical, er diagnosticeringsmulighederne blevet meget bedre....
1 2 3 15

Nyheder

Døren til et sukker-univers går op
17. august 2018
Unge danske talenter på unikt forskningsophold i Californien
7. august 2018
Derfor kan det hjælpe at give elektrochok 
17. juli 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge